Dapagliflozin

Drug Profile

Dapagliflozin

Alternative Names: BMS-512148; Dapagliflozin propanediol; Farxiga; Forxiga; Oxra

Latest Information Update: 19 Jul 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bristol-Myers Squibb; Ono Pharmaceutical; Uppsala University
  • Class Antihyperglycaemics; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Chronic heart failure; Renal failure; Type 1 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 11 Jul 2017 AstraZeneca announces intention to submit regulatory appliocations for Type-2 diabetes mellitus (add-on therapy, patients at high risk of a cardiovascular event) in USA and European Union in 2020 (AstraZeneca pipeline, July 2017)
  • 11 Jul 2017 AstraZeneca announces intention to submit regulatory filings for Chronic heart failure in USA, Japan, China and European Union in 2020 (AstraZeneca pipeline, July 2017)
  • 11 Jul 2017 AstraZeneca announces intention to submit regulatory filings for Renal failure in USA, China and European Union in 2021 (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top